静注人免疫球蛋白在新型冠状病毒肺炎治疗中的应用  

Research progress of human intravenous immunoglobulin in the treatment ofCOVID-19

作　　者：张巍 徐继轩 王宗奎[1] 马莉[1] 李长清[1] ZHANG Wei;XU Jixuan;WANG Zongkui;MA Li;LI Changqing(Institute of Blood Transfusion,Chinese Academy of Medical Sciences and Peking.Union Medical College,Chengdu 610052,China)

机构地区：[1]中国医学科学院北京协和医学院输血研究所,四川成都610052

出　　处：《中国输血杂志》2021年第5期547-556,共10页Chinese Journal of Blood Transfusion

摘　　要：新型冠状病毒肺炎(COVID-19)给全球的经济、社会以及卫生健康系统带来了巨大的破坏和冲击。静注人免疫球蛋白(IVIG)作为1种从健康人体血液中提取制备的血液制品,在本次抗击疫情中发挥了积极作用。本文详细梳理了IVIG治疗COVID-19的中国方案、专家共识以及文献报道,阐述了其可能的作用机制,以期为COVID-19治疗药物的筛选提供参考。COVID-19 has brought huge damage and impact to the economy, society and healthy systems of China and the world. As a blood product prepared from healthy human blood, human intravenous immunoglobulin have played an active role in the fight against the epidemic. This article summarized the treatment plans, expert consensus and clinical reports in China concerning immunoglobulin in the treatment of COVID-19, and discussed the related possible mechanism of action, aiming at providing references for the drugs screening of COVID-19.

关 键 词：静注人免疫球蛋白 新型冠状病毒肺炎 作用机制 

分 类 号：R457.1[医药卫生—治疗学] R563.1[医药卫生—临床医学]